SciSparc Ltd. Collaboration Leads to Patent Application for Depression Therapy

SciSparc Ltd., through its majority-owned subsidiary NeuroThera Labs Inc., announced that a patent application has been filed by Clearmind Medicine Inc. in Hong Kong for a novel combination therapy for major depressive disorder (MDD). This therapy combines Clearmind's MEAI with NeuroThera-sourced Palmitoylethanolamide (PEA). The filing highlights the potential of this MEAI-PEA synergy as a non-hallucinogenic neuroplastogen option for depression treatment. The company believes this therapy could offer a safer, more accessible, and affordable alternative to existing antidepressants. SciSparc's ongoing drug development programs include SCI-110 for Tourette syndrome and Alzheimer's disease, and SCI-210 for ASD and status epilepticus. NeuroThera Labs is focused on developing therapeutics for central nervous system disorders.